Skip to content

Insurance broker registered with SUSEP 212130733

NeuCorr Seguros

NeuCorr Seguros

Brazil's Clinical Research Law (14.874/2024): What Sponsors Need to Know

Brazil's Law 14.874/2024 reinforced sponsor duties to indemnify trial participants. What international sponsors and CROs need to know before submission.

In May 2024 Brazil enacted Law 14.874/2024, a new legal framework for clinical research with human subjects, regulated in October 2025 by Decree 12.651. For international sponsors and CROs, it signals two things at once: Brazil wants to attract more studies by giving research more legal certainty — and it keeps the protection of participants firmly at the centre. Here is what matters for your study and its insurance.

What the law does

Law 14.874/2024 created the National System of Ethics in Research with Human Subjects, modernising the governance of ethical review with the stated goals of legal certainty, less bureaucracy and faster analysis timelines. The broader aim, echoed by the Ministry of Health when the law was regulated, is to make Brazil a more competitive destination for clinical research and innovation.

For a study team, the practical headline is that the framework around participant protection is now set out in primary legislation rather than resting only on ethics resolutions.

The law keeps the sponsor responsible for protecting participants. In particular, the sponsor must:

  • Indemnify participants for damage suffered as a result of taking part in the research;
  • Provide the health assistance related to that damage;
  • After the trial, ensure the free supply of the investigational product when the responsible investigator considers it the best therapeutic option.

The law also distinguishes indemnification (for harm) from reimbursement — the latter defined as covering the participant’s material expenses, such as transport and meals.

What it means for insurance

The law does not name “insurance” as the sole mechanism, but the sponsor’s duty to guarantee assistance and indemnification remains — and, in practice, a locally admitted insurance policy is how sponsors evidence that guarantee to the ethics system. If anything, a clearer legal duty makes getting the insurance structure right even more important. International sponsors should ensure a Brazil-admitted policy, coordinated with their global program, is arranged before ethics submission — see do you need a local insurance policy for a clinical trial in Brazil? and our pillar guide on clinical trial insurance in Brazil.

NeuCorr is a Brazilian broker registered with SUSEP and specialised in clinical research risk. We can help you structure the participant guarantee in line with the new framework — contact our team.

This content is informational and does not replace specific legal, regulatory or insurance advice for your study.

FAQ

What is Law 14.874/2024?
It is Brazil's clinical research law, enacted on 28 May 2024 and regulated by Decree 12.651 of October 2025. It created the National System of Ethics in Research with Human Subjects and set out the protection and compensation of research participants and the responsibilities of sponsors and investigators.
Does the law require insurance?
The law reinforces the sponsor's duty to indemnify participants for study-related harm and to provide related health assistance. It does not isolate the word 'insurance' as the only mechanism, but a locally admitted insurance policy remains the usual, most robust way to evidence that financial guarantee to the ethics system.
What changes for international sponsors?
The law aims to give more legal certainty and faster ethics review to attract investment. Sponsor duties to protect participants remain firm, so international sponsors should ensure their participant guarantee — typically a locally admitted policy coordinated with their global program — is in place before ethics submission.
Chat with us